Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Advanced Solid Tumours 2Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Neoplasms by Site 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lung Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1Advanced Solid Malignancies 1

Interventions

tremelimumab 1olaparib 1durvalumab 1ceralasertib 1adavosertib 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma × ceralasertib × Clear all
NCT02937818 2024-06-07

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

AstraZeneca

Phase 2 Completed
72 enrolled 29 charts
Thoracic

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡